Cizzle Bio Featured in CEO/CFO Magazine: A Visionary Interview with CEO Bill Behnke

Press Release
Written By Cizzle Bio, Inc.
Portrait of Bill Behnke, CEO of Cizzle Bio, alongside a quote about making early cancer detection more accessible, featured in CEO/CFO Magazine interview.

We’re proud to share that Cizzle Bio was recently featured in CEO/CFO Magazine, where our CEO Bill Behnke provided a comprehensive overview of our mission, breakthroughs, and vision for the future of cancer diagnostics.

In this exclusive interview, Bill highlights:

  • Cizzle Bio’s focus on early cancer detection through minimally invasive blood tests targeting high-burden cancers.

  • The science behind CIZ1B, our biomarker for early-stage lung cancer detection, and its potential to transform patient outcomes.

  • The development of DEX-G2, our gastric cancer test, built on a powerful 10-miRNA signature with exceptional sensitivity and specificity.

  • Our strategy for U.S. commercialization, clinical partnerships, and future growth—including expansion into underserved areas and global markets.

This feature reinforces our position at the forefront of diagnostic innovation and emphasizes how early detection can save lives.

Read the full interview: CEO/CFO Magazine – Cizzle Bio

Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Next

Cizzle Bio Launches Cancer Blood Tests in the Cayman Islands